Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
Author: Baccarani, M.
Druker, B.
Branford, S.
Kim, D.
Pane, F.
Mongay, L.
Mone, M.
Ortmann, C.
Kantarjian, H.
Radich, J.
Hughes, T.
Cortes, J.
Guilhot, F.
Citation: International Journal of Hematology, 2014; 99(5):616-624
Publisher: Springer Japan
Issue Date: 2014
ISSN: 0925-5710
Statement of
Michele Baccarani; Brian J. Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Lidia Mongay; Manisha Mone; Christine-Elke Ortmann; Hagop M. Kantarjian; Jerald P. Radich; Timothy P. Hughes; Jorge E. Cortes; François Guilhot
Abstract: Abstract not available
Keywords: Imatinib; Chronic myeloid leukemia; Phase 3 clinical trial; BCR-ABL; Tyrosine kinase inhibitor
Rights: © The Japanese Society of Hematology 2014
RMID: 0020138738
DOI: 10.1007/s12185-014-1566-2
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.